Clinical Trial Update: Malignant Pleural Effusion With ZD6474 [Phase 2]

View source ↗

Summary

Phase 2 study of ZD6474 (vandetanib) for malignant pleural effusion in lung cancer sponsored by MD Anderson Cancer Center was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Malignant Pleural Effusion

Drugs mentioned

• ZD6474 (vandetanib) (vandetanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer, Pleural Effusion | Phase 2 | Status: TERMINATED | Results posted: 2016-03-09